PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Anterior Ischemic Optic Neuropathy Clinical Trial

Official title:
Prospective Case Crossover Study to Assess Whether PDE5 Inhibitor Exposure in Men Increases the Risk for the Development of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Status Terminated

Clinical Trial Summary

The primary objective of this study is to determine whether the use of PDE5 inhibitors (vardenafil, sildenafil, or tadalafil) increases the risk for the development of NAION.

Clinical Trial Description

Collected data will be compared to historic data of the same participant in case-crossover design. ;

Study Design

Related Conditions & MeSH terms

Anterior Ischemic Optic Neuropathy
Ischemia
Optic Nerve Diseases
Optic Neuritis
Optic Neuropathy, Ischemic
Peripheral Nervous System Diseases

Clinical Trial Details

NCT number	NCT00867815
Study type	Interventional
Source	Bayer
Contact
Status	Terminated
Phase	Phase 4
Start date	July 13, 2009
Completion date	March 28, 2018

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05749094` - Optic Nerve Sheath Ultrasound in Giant Cell Arteritis
Withdrawn	`NCT01607671` - Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%	Phase 1
Completed	`NCT03401892` - Retinal Neuro-vascular Coupling in Patients With Non-arteritic Anterior Ischemic Optic Neuropathy	N/A
Recruiting	`NCT01768260` - Effect of EECP on Anterior Ischemic Optic Neuropathy	N/A
Completed	`NCT01260324` - Epidemiology Study of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)